ES2859559T3 - Péptidos miméticos - Google Patents

Péptidos miméticos Download PDF

Info

Publication number
ES2859559T3
ES2859559T3 ES13792995T ES13792995T ES2859559T3 ES 2859559 T3 ES2859559 T3 ES 2859559T3 ES 13792995 T ES13792995 T ES 13792995T ES 13792995 T ES13792995 T ES 13792995T ES 2859559 T3 ES2859559 T3 ES 2859559T3
Authority
ES
Spain
Prior art keywords
seq
peptide
apoa
mimetic
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13792995T
Other languages
English (en)
Spanish (es)
Inventor
Nicolas Vuilleumier
Sabrina Pagano
Oliver Hartley
Hubert Gaertner
Teixeira Priscila Camillo
Paul Cutler
Philippe Ferber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
University of Geneva
University Hospital of Geneva
Original Assignee
F Hoffmann La Roche AG
University of Geneva
University Hospital of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, University of Geneva, University Hospital of Geneva filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2859559T3 publication Critical patent/ES2859559T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
ES13792995T 2012-11-06 2013-11-06 Péptidos miméticos Active ES2859559T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12191474 2012-11-06
PCT/IB2013/059948 WO2014072916A1 (en) 2012-11-06 2013-11-06 Mimetic peptides

Publications (1)

Publication Number Publication Date
ES2859559T3 true ES2859559T3 (es) 2021-10-04

Family

ID=47115623

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13792995T Active ES2859559T3 (es) 2012-11-06 2013-11-06 Péptidos miméticos

Country Status (11)

Country Link
US (1) US10087234B2 (enExample)
EP (1) EP2917234B1 (enExample)
JP (1) JP6499967B2 (enExample)
KR (1) KR102215175B1 (enExample)
CN (1) CN104768970B (enExample)
BR (1) BR112015010276A2 (enExample)
CA (1) CA2888657C (enExample)
ES (1) ES2859559T3 (enExample)
MX (1) MX364626B (enExample)
RU (1) RU2662973C2 (enExample)
WO (1) WO2014072916A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018210404B2 (en) * 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
SG11202010016QA (en) * 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
MX2020010716A (es) 2018-04-10 2021-03-09 Sanofi Aventis Deutschland Metodo para escindir de la fase solida peptidos unidos a una fase solida.
CN108948158B (zh) * 2018-07-21 2021-06-15 河南大学 四连接素模拟肽tnp及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
EP1706131A4 (en) 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
WO2007022248A2 (en) * 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
AU2008266753A1 (en) 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
AU2012249301A1 (en) * 2011-04-29 2013-11-21 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents

Also Published As

Publication number Publication date
WO2014072916A1 (en) 2014-05-15
KR20150082350A (ko) 2015-07-15
MX2015005761A (es) 2015-08-12
US10087234B2 (en) 2018-10-02
CA2888657C (en) 2022-05-03
US20150291682A1 (en) 2015-10-15
RU2662973C2 (ru) 2018-07-31
MX364626B (es) 2019-05-03
RU2015121688A (ru) 2016-12-27
JP2016505514A (ja) 2016-02-25
EP2917234A1 (en) 2015-09-16
CN104768970A (zh) 2015-07-08
EP2917234B1 (en) 2020-12-02
CN104768970B (zh) 2019-11-15
KR102215175B1 (ko) 2021-02-15
BR112015010276A2 (pt) 2019-10-15
CA2888657A1 (en) 2014-05-15
JP6499967B2 (ja) 2019-04-10

Similar Documents

Publication Publication Date Title
ES2317845T3 (es) Uso de un polipeptido para detectar un estado patologico asociado con la esclerosis en placas.
AU2010234942B2 (en) Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
KR100881900B1 (ko) 항-오스테오폰틴 항체 및 그 용도
US20200087374A1 (en) Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
US10087234B2 (en) Mimetic peptides
CN108184330A (zh) 抗原肽及其用于诊断和治疗自闭症的用途
Pozzi et al. Chemical synthesis and characterization of wild‐type and biotinylated N‐terminal domain 1–64 of β2‐glycoprotein I
Ancsin et al. Laminin interactions with the apoproteins of acute-phase HDL: preliminary mapping of the laminin binding site on serum amyloid A
JP2016516726A (ja) ネフローゼ症候群及び関連状態の治療方法
Dong et al. Cyclic peptide RD808 reduces myocardial injury induced by β1-adrenoreceptor autoantibodies
PT972032E (pt) Péptidos para o tratamento do lúpos eritematoso agudo disseminado
WO2008096905A1 (ja) 抗ｂｒａｋ（ｃｘｃｌ１４）ヒトモノクローナル抗体及びその用途
KR102025446B1 (ko) 프로필라그린 c 말단 도메인 특이적 항체 및 그의 용도
Beaino et al. Thiopalmitoylated peptides from the peripheral nervous system myelin p0 protein: synthesis, characterization, and neuritogenic properties
Makker et al. Renal antigens in mercuric chloride induced, anti-GBM autoantibody glomerular disease
CN1403819A (zh) 抗α－胞衬蛋白多肽抗体测定在干燥综合征诊断中的应用
JP4557421B2 (ja) 自己免疫疾患を治療するためのフィラグリン由来シトルリンペプチドの使用
WO2015021291A2 (en) Antibodies to acetylated cyclophilin and use thereof
US20090227501A1 (en) Agents for preventing and/or treating upper digestive tract disorders
US7419664B2 (en) Method of treatment using antibody to CLCA-1
JP2006180704A (ja) 新規タンパクおよびその用途
WO2005044846A1 (ja) アドレノメデュリン２およびその用途
JP2004159654A (ja) 抗体およびその用途